Molecular Templates (MTEM) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development o ... f its innovative proprietary Engineered Toxin Body (ETB) platform. MTEM’s first immunotoxin, MT-3724, is in clinical development for non-Hodgkin’s lymphoma. Pipeline products for additional oncology targets are being advanced toward clinical development. For more information, please visit MTEM’s website at www.mtem.com. read more